Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice-6 months results of the BICSTaR cohort

被引：0
|
作者：
Esser, S. [1 ]
Jessen, H. [2 ]
Schneider, J. [3 ]
Schellberg, S. [4 ]
Stellbrink, H-J [5 ]
Waizmann, M. [6 ]
Hillenbrand, H. [7 ]
Bilbao, P. [8 ]
Schreiber, S. [9 ]
Thorpe, D. [8 ]
Ramroth, H. [8 ]
Haubrich, R. [10 ]
Heinzkill, M. [9 ]
机构：
[1] Univ Hosp Essen, Clin Dermatol, Dept Venerol, Essen, Germany
[2] Praxis Jessen Kollegen, Berlin, Germany
[3] Tech Univ Munich, Sch Med, Univ Hosp Rechts Del Isar, Dept Med 2, Munich, Germany
[4] Novopraxis Berlin GbR, Berlin, Germany
[5] ICH Study Ctr, Hamburg, Germany
[6] Praxis Waizmann, Leipzig, Germany
[7] MVZ Praxis City Ost, Berlin, Germany
[8] Gilead Sci Europe Ltd, Uxbridge, Middx, England
[9] Gilead Sci GmbH, Munich, Germany
[10] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/16
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [21] Effectiveness, safety and tolerability of dolutegravir/lamivudine versus tenofovir alafenamide/emtricitabine/bictegravir in a real-life cohort of HIV-1 virologically suppressed treatment experienced people living with HIV
    Tordi, S.
    De Socio, G. V.
    Altobelli, D.
    Gidari, A.
    Zoffoli, A.
    Francisci, D.
    HIV MEDICINE, 2023, 24 : 153 - 155
  • [22] 24-Month (24M) effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive (TN) and treatment-experienced (TE) people living with HIV in the BICSTaR study
    Garcia-Deltoro, Miguel
    Waizmann, Michael
    Robineau, Olivier
    Wong, Alexander
    Shahar, Eduardo
    Lambert, John S.
    van Welzen, Berend
    Boffito, Marta
    Yokomaku, Yoshiyuki
    Cassidy, Tali
    Marongiu, Andrea
    Thorpe, David
    Heinzkill, Marion
    Lluis-Ganella, Carla
    Di Perri, Giovanni
    HIV MEDICINE, 2023, 24 : 23 - 23
  • [23] Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naive HIV-1 infected patients-24-month results from the German TAFNES cohort study
    Pauli, R.
    Jessen, H.
    Postel, N.
    Heuchel, T.
    Rieke, A.
    Hillenbrand, H.
    Kuemmerle, T.
    Schreiber, S.
    Goerner, K.
    Heinzkill, M.
    Haubrich, R.
    Stellbrink, H-J
    HIV MEDICINE, 2019, 20 : 54 - 55
  • [24] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive people with both HIV-1 and hepatitis B: 3-year outcomes from ALLIANCE
    Avihingsanon, Anchalee
    Lu, Hongzhou
    Leong, Chee Loon
    Hung, Chien-Ching
    Kiertiburanakul, Sasisopin
    Lee, Man-Po
    Supparatpinyo, Khuanchai
    Madera, Sharline
    Wang, Hongyuan
    Hindman, Jason
    Li, Taisheng
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 323 - 324
  • [25] Comparing lamivudine plus dolutegravir and bictegravir/emtricitabine/ tenofovir alafenamide in antiretroviral therapynaive HIV-infected patients: preliminary results from clinical practice
    Long, H.
    HIV MEDICINE, 2023, 24 : 105 - 106
  • [26] Use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in kidney transplant recipients living with HIV-1 receiving calcineurin and mTOR inhibitors: a pilot switch study
    Gallien, Sebastien
    Assoumou, Lambert
    Dantal, Jacques
    Hulin, Anne
    Benalycherif, Aida
    Ben Rayana, Raida
    Tobbal, Yasmine
    Matignon, Marie
    Melica, Giovanna
    Allavena, Clotilde
    Stehle, Thomas
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 286 - 287
  • [27] Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + another 3rd agent in HIV-1+patients over 24 months - Results from the German TAFNES cohort study
    Stellbrink, H.
    Scholten, S.
    Hillenbrand, H.
    Knechten, H.
    Jessen, H.
    Schreiber, S.
    Goerner, K.
    Haubrich, R.
    Heinzkill, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 54 - 55
  • [28] 24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients
    Knechten, H.
    Schneeweiss, S.
    Schuebel, N.
    Hillenbrand, H.
    Kuemmerle, T.
    Schreiber, S.
    Goerner, K.
    Heinzkill, M.
    Haubrich, R.
    Stellbrink, H-J
    HIV MEDICINE, 2019, 20 : 60 - 61
  • [29] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV (PLWH): 12-month (12M) effectiveness, persistence and safety in a multi-country cohort study
    Mallolas, Josep
    Esposito, Vincenzo
    Hocqueloux, Laurent
    Lambert, John S.
    Levy, Itzchak
    Wyen, Christoph
    van Welzen, Berend
    Ustianowski, Andrew
    Schreiber, Sandra
    Thorpe, David
    Heinzkill, Marion
    Marongiu, Andrea
    Haubrich, Richard
    Loemba, Hugues
    HIV MEDICINE, 2022, 23 : 29 - 29
  • [30] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV (PLWH): 12-month (12M) effectiveness, persistence, and safety in a multi-country cohort study
    Mallolas, J.
    Esposito, V.
    Hocqueloux, L.
    Lambert, J. S.
    Levy, I.
    Wyen, C.
    van Welzen, B.
    Ustianowski, A.
    Schreiber, S.
    Thorpe, D.
    Heinzkill, M.
    Marongiu, A.
    Haubrich, R.
    Loemba, H.
    HIV MEDICINE, 2021, 22 : 115 - 116
12345